Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 2,153 Shares of Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Oxana Beskrovnaya sold 2,153 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $11.38, for a total transaction of $24,501.14. Following the completion of the transaction, the insider now directly owns 195,840 shares of the company’s stock, valued at approximately $2,228,659.20. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Oxana Beskrovnaya also recently made the following trade(s):

• On Tuesday, February 18th, Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock. The stock was sold at an average price of $13.95, for a total value of $36,242.10.

Dyne Therapeutics Stock Down 3.9 %

NASDAQ DYN opened at $11.88 on Friday. The firm has a market capitalization of $1.34 billion, a PE ratio of -3.34 and a beta of 1.11. The stock’s 50 day moving average is $15.10 and its 200 day moving average is $25.73. Dyne Therapeutics, Inc. has a twelve month low of $11.18 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Hedge Funds Weigh In On Dyne Therapeutics

A number of hedge funds have recently added to or reduced their stakes in DYN. FMR LLC boosted its position in shares of Dyne Therapeutics by 69.7% during the third quarter. FMR LLC now owns 9,026,697 shares of the company’s stock valued at $324,239,000 after buying an additional 3,707,734 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company’s stock valued at $173,808,000 after buying an additional 566,146 shares during the period. RTW Investments LP boosted its stake in shares of Dyne Therapeutics by 6.8% in the 3rd quarter. RTW Investments LP now owns 6,818,641 shares of the company’s stock worth $244,926,000 after buying an additional 431,503 shares during the last quarter. RA Capital Management L.P. grew its holdings in shares of Dyne Therapeutics by 5.5% in the third quarter. RA Capital Management L.P. now owns 6,381,144 shares of the company’s stock worth $229,211,000 after acquiring an additional 331,940 shares during the period. Finally, State Street Corp increased its position in Dyne Therapeutics by 13.8% during the third quarter. State Street Corp now owns 3,641,859 shares of the company’s stock valued at $130,816,000 after acquiring an additional 440,890 shares during the last quarter. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on DYN shares. Robert W. Baird initiated coverage on Dyne Therapeutics in a research report on Friday, December 13th. They set an “outperform” rating and a $46.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. Piper Sandler reduced their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. HC Wainwright decreased their price target on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Finally, Chardan Capital reissued a “buy” rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $48.85.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.